Boehringer Ingelheim announces BVDzero Case Awards 2020

Ingelheim, Germany, 9 December 2019 - Boehringer Ingelheim, a leader in the animal health industry worldwide, is announcing the 2020 ‘BVDzero Case Awards’, now open for applications. The awards reflect Boehringer Ingelheim’s long-term commitment to promoting the health and well-being of farm animals.

The company will provide a total prize of 15,000 euros for the top 10 clinical cases entered. Any person involved in the cattle industry is eligible for participation. Areas of expertise include, but are not limited to, research, diagnostics, animal science, veterinary practice, production veterinary medicine, cattle production and animal health & welfare. The list of the 2018 winners which also includes the awarded amounts is available here.

Through the ‘BVDzero Case Awards’, Boehringer Ingelheim aims to encourage the search for both clinical and subclinical cases of BVD (Bovine viral diarrhea) in cattle herds. The company believes that it will help increase the awareness of BVD and, as a result, help reduce its prevalence. Applications can be submitted until 20 March 2020.

“Bovine viral diarrhea is one of the most common diseases in cattle, causing harm to the affected animals and huge economic damage to the livestock industry. We aim to challenge the status quo and bring a paradigm shift in the control of BVD globally,” explained Steve Williams, Head of Global Ruminants/Cattle Strategic Business Unit at Boehringer Ingelheim.

The award ceremony will take place at this year’s BVDzero Press Conference held in May 2020. The winners will be selected by the BVDzero Committee, consisting of renowned external experts in the field of bovine health.

More information is available on BVDzero website.

Boehringer Ingelheim Animal Health Business Unit

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of almost 4 billion euros in 2018 and presence in more than 150 markets.

Across the globe, our 10,000 employees create the future of animal wellbeing through their daily work. We believe in prevention over treatment and therefore, we focus on developing innovative solutions in the field of vaccines, parasiticides and therapeutics. With a large portfolio of advanced, preventive healthcare products, tools and services, we support our customers in taking care of the health of their animals.

For more information visit: www.boehringer-ingelheim.com/animal-health/overview

Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: https://annualreport.boehringer-ingelheim.com.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.